Translatability barriers between preclinical and clinical trials of AAV gene therapy in inherited retinal diseases

Vision Res. 2023 Sep:210:108258. doi: 10.1016/j.visres.2023.108258. Epub 2023 May 25.

Abstract

Inherited retinal diseases (IRDs) are progressive degenerative diseases which cause gradual vision loss or complete blindness. As over 270 gene mutations have been identified in the underlying pathology of IRDs, gene therapy as a treatment modality has been an increasingly active realm of investigation. Currently, the most common vehicle of ocular gene delivery is the adeno-associated virus (AAV) vector. This is injected into the immune-privileged subretinal space to mediate transgene expression in retinal cells. Although numerous animal models of IRDs have demonstrated successful outcomes following AAV-mediated gene delivery, many of these studies fail to translate into successful outcomes in clinical trials. The purpose of this review is to A) comparatively assess preclinical and clinical IRD trials in which the success of AAV-mediated therapy failed to translate between animal and human participants B) discuss factors which may complicate the translatability of gene therapy in animals to results in humans.

Keywords: AAV; Gene therapy; Inherited retinal disease; Viral vector.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Dependovirus* / genetics
  • Genetic Therapy / methods
  • Humans
  • Models, Animal
  • Retina / metabolism
  • Retinal Diseases* / genetics
  • Retinal Diseases* / metabolism
  • Retinal Diseases* / therapy